Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2018: the Influenza Complications Alert Network (FluCAN)
DOI:
https://doi.org/10.33321/cdi.2019.43.48Keywords:
influenza, public health surveillance, influenza vaccines, vaccination coverage, vaccine effectivenessAbstract
The Influenza Complications Alert Network (FluCAN) is a sentinel hospital-based surveillance program that operates at sites in all jurisdictions in Australia. This report summarises the epidemiology of hospitalisations with laboratory-confirmed influenza during the 2018 influenza season.
In this observational surveillance system, cases were defined as patients admitted to any of the 17 sentinel hospitals with influenza confirmed by nucleic acid detection. Data were also collected on a frequency-matched control group of influenza-negative patients admitted with acute respiratory infection.
During the period 3 April to 31 October 2018 (the 2018 influenza season), 769 patients were admitted with confirmed influenza to one of 17 FluCAN sentinel hospitals. Of these, 30% were elderly (≥65 years), 28% were children (<16 years), 6.4% were Aboriginal and Torres Strait Islander peoples, 2.2% were pregnant and 66% had chronic comorbidities. A small proportion of FluCAN admissions were due to influenza B (13%). Estimated vaccine coverage was 77% in the elderly (≥65 years), 45% in non-elderly adults with medical comorbidities and 26% in children (<16 years) with medical comorbidities. The estimated vaccine effectiveness (VE) in the target population was 52% (95% CI: 37%, 63%).
There were a smaller number of hospital admissions detected with confirmed influenza in this national observational surveillance system in 2018 than in 2017, with the demographic profile reflecting the change in circulating subtype from A/H3N2 to A/H1N1.
Downloads
References
GBD 2017 Influenza Collaborators. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2019;7(1):69–89.
Cassini A, Colzani E, Pini A, Mangen MJ, Plass D, McDonald SA et al. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013. Euro Surveill. 2018;23(16). https://doi.org/10.2807/1560-7917.ES.2018.23.16.17-00454.
Li-Kim-Moy J, Yin JK, Patel C, Beard FH, Chiu C, Macartney KK et al. Australian vaccine preventable disease epidemiological review series: Influenza 2006 to 2015. Commun Dis Intell Q Rep. 2016;40(4):E482–95.
Kelly PM, Kotsimbos T, Reynolds A, Wood-Baker R, Hancox B, Brown SG et al. FluCAN 2009: initial results from sentinel surveillance for adult influenza and pneumonia in eight Australian hospitals. Med J Aust. 2011;194(4):169–74.
AIHW. Hospital resources 2016–17: Australian hospital statistics. Canberra: Australian Institute for Health and Welfare; 2018. Available from: https://www.aihw.gov.au/reports/hospitals/ahs-2016-17-hospital-resources/contents/table-of-contents
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55.
Dyda A, Karki S, Hayen A, MacIntyre CR, Menzies R, Banks E et al. Influenza and pneumococcal vaccination in Australian adults: a systematic review of coverage and factors associated with uptake. BMC Infect Dis. 2016;16(1):515.
Domnich A, Arata L, Amicizia D, Puig-Barbera J, Gasparini R, Panatto D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. Vaccine. 2017;35(4):513–20.
Wilkinson K, Wei Y, Szwajcer A, Rabbani R, Zarychanski R, Abou-Setta AM et al. Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis. Vaccine. 2017;35(21):2775–80.
DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635–45.
Gravenstein S, Davidson HE, Taljaard M, Ogarek J, Gozalo P, Han L et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. Lancet Respir Med. 2017;5(9):738–46.
Shay DK, Chillarige Y, Kelman J, Forshee RA, Foppa IM, Wernecke M et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries in preventing postinfluenza deaths during 2012–2013 and 2013–2014. J Infect Dis. 2017;215(4):510–7.
Izurieta HS, Thadani N, Shay DK, Lu Y, Maurer A, Foppa IM et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis. 2015;15(3):293–300.
Mannino S, Villa M, Apolone G, Weiss NS, Groth N, Aquino I et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol. 2012;176(6):527–33.
Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942–51.
Skowronski DM, Leir S, Sabaiduc S, Murti M, Dickinson JA, Olsha R et al. Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019. Euro Surveill. 2019;24(4). https://doi.org/10.2807/1560-7917.ES.2019.24.4.1900055.
Britton PN, Blyth CC, Macartney K, Dale RC, Li-Kim-Moy J, Khandaker G, et al. The spectrum and burden of influenza-associated neurological disease in children: combined encephalitis and influenza sentinel site surveillance from Australia, 2013–2015. Clin Infect Dis. 2017;65(4):653–60.
Rajaram S, Steffey A, Blak B, Hickman M, Christensen H, Caspard H. Uptake of childhood influenza vaccine from 2012–2013 to 2014–2015 in the UK and the implications for high-risk children: a retrospective observational cohort study. BMJ Open. 2016;6(8):e010625.
Rajaram S, Wiecek W, Lawson R, Blak BT, Zhao Y, Hackett J et al. Impact of increased influenza vaccination in 2-3-year-old children on disease burden within the general population: A Bayesian model-based approach. PLoS One. 2017;12(12):e0186739.
Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TS, Al Mamun A et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014;2(5):395–404.
Bongard E, van der Velden AW, Cook J, Saville B, Beutels P, Munck Aabenhus R et al. Antivirals for influenza-Like Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary CarE (ALIC4E): the ALIC4E protocol. BMJ Open. 2018;8(7):e021032.
Ainslie KEC, Shi M, Haber M, Orenstein WA. On the bias of estimates of influenza vaccine effectiveness from test-negative studies. Vaccine. 2017;35(52):7297–301.
Lewnard JA, Tedijanto C, Cowling BJ, Lipsitch M. Measurement of vaccine direct effects under the test-negative design. Am J Epidemiol. 2018;187(12):2686–97.
Published
How to Cite
License
Copyright (c) 2019 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
